BMS to Present Results of Breyanzi (lisocabtagene maraleucel) in P-II (PILOT) Study for R/R Large B-cell Lymphoma at ASCO 2022
Shots:
- The P-II (PILOT) study evaluates Breyanzi in 61 adults with r/r LBCL after 1L therapy who are ineligible for HSCT
- The results showed a reduction in disease, 80% responds to treatment at a median follow-up of 12.3mos. 54% achieved CR, responses were durable with a median DoR of 12.1mos. at a median follow-up of 15.5mos., m-DoR (21.7mos.), m-PFS (9.0mos.) & m-OS (not reached), manageable safety profile with no new safety signals, low rates of sev. CRS or neurologic events with no grade 4/5 CRS or neurologic events
- In PROs analysis, improvements in fatigue, pain & overall lymphoma symptoms. In patient-level analysis, 70% improved health-related QoL @6mos. Breyanzi’s sBLA is under US FDA's Priority Review with an anticipated PDUFA date of June 24, 2022
Ref: BMS | Image: BMS
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.